Clinical trials: Malignancies Multiple
Multiple Myeloma
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC) in participants with multiple myeloma (MM) who have received…
- Trial name
- CEVOLUTION (NCT07555938)
- Testing
- Cevostamab, Pomalidomide, Dexamethasone
- Where
- 93 sites in United States, Australia and 16 more
- Volunteers
- 380 people
- Sponsor
- Hoffmann-La Roche
Hepatic Impairment, Healthy Participants
Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic Impairment
The purpose of this study is to assess the drug levels and safety of BMS-986278 in participants with mild, moderate, and severe Hepatic Impairment (HI), and in matched healthy control participants with normal hepatic function.
- Trial name
- NCT06425198
- Testing
- BMS-986278
- Where
- 4 sites in United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Multiple Myeloma
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
This study is designed to evaluate if treatment with adjuvant nivolumab improves depth of response in patients with relapsed refractory multiple myeloma (RRMM) who achieve a less-than-ideal response to idecaptagene vicleucel.
- Trial name
- NCT06523621
- Testing
- Nivolumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Wake Forest University Health Sciences
Advanced Cancer
Study of HC006 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors
This is an open-label, multicenter Phase 1b clinical study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy of HC006 in combination with a PD-1 inhibitor in patients with advanced…
- Trial name
- NCT06963814
- Testing
- HC006, KEYTRUDA ®( Pembrolizumab)
- Where
- China
- Volunteers
- 252 people
- Sponsor
- HC Biopharma Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndrome
A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Phase 1a is an open-label, multi-dose, single-arm, dose-escalation study to define the toxicity profile, pharmacokinetics, and antitumor activity of SGN-33 in patients with myelodysplastic syndrome (MDS), acute myelogenous…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia
- Trial name
- NCT00283114
- Testing
- lintuzumab
- Where
- 9 sites in United States
- Volunteers
- 82 people
- Sponsor
- Seagen Inc.
HER2-positive Breast Cancer, Neoadjuvant Therapy
Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05)
This study is a prospective, single arm, multi-center clinical trial. The primary study objective is to evaluate the pathologic complete response (pCR）and clinical complete response（cCR) of neodjuvant treatment of HER2-positive…
- Conditions
- HER2-positive Breast Cancer, Neoadjuvant Therapy, Pyrotinib
- Trial name
- NCT06832904
- Testing
- pyrotinib and trastuzumab in combinition with neoadjuvant chemotherapy
- Where
- China
- Volunteers
- 33 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)
This phase II MATCH treatment trial tests how well larotrectinib (LOXO-101) works in treating patients with cancer that has certain genetic changes.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
- Trial name
- NCT06390852
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma
The purpose of this post marketing study is to determine the plasma concentration of bortezomib (unchanged drug) to assess the pharmacokinetic (PK - the study of the way a drug enters and leaves the blood and tissues over time)…
- Trial name
- NCT01801436
- Testing
- Bortezomib
- Volunteers
- 14 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)
This phase II MATCH treatment trial identifies the effects of copanlisib hydrochloride (copanlisib) in patients whose cancer has a genetic change called PIK3CA mutation.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm, Refractory Lymphoma
- Trial name
- NCT05490771
- Testing
- Biopsy Procedure, Computed Tomography, Copanlisib Hydrochloride
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, Multiple Myeloma
An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
The goal of this study is to evaluate the feasibility and preliminary efficacy of an artificial intelligence (AI)-generated personalized question prompt list (a list of suggested questions to ask during outpatient appointments)…
- Trial name
- NCT07226934
- Testing
- GPT-QPL
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Washington University School of Medicine
Multiple Myeloma
Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone in Elderly Myeloma Patients
The purpose of this study is to determine whether the association of Thalidomide to Melphalan and Prednisone is effective in the treatment of newly diagnosed elderly multiple myeloma.
- Trial name
- NCT00232934
- Testing
- Thalidomide
- Where
- 13 sites in Italy
- Volunteers
- 400 people
- Sponsor
- Gruppo Italiano per lo Studio del Mieloma Multiplo
Urothelial Carcinoma
A Prospective, Multi-centre, Single-blinded Study of UroCAD for Urothelial Carcinoma Diagnosis and Follow-up
Urothelial carcinoma (UC) is common malignancy and is considered to be one of the costliest cancers. The traditional diagnostic methods of UC present with some shortcomings.
- Trial name
- NCT04432909
- Testing
- The level of CNV
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Changhai Hospital
Neoplasms
A Study to Evaluate Safety, Pharmacokinetics, and Efficacy of RO6895882 in Participants With Advanced and/or Metastatic Solid Tumors
This open-label, multi-center, dose-escalation study will evaluate the safety, pharmacokinetics, and therapeutic activity of RO6895882 in participants with Carcinoembryonic Antigen (CEA)-positive solid tumors who have progressed…
- Trial name
- NCT02004106
- Testing
- RO6895882
- Where
- 10 sites in United States, Denmark and 6 more
- Volunteers
- 110 people
- Sponsor
- Hoffmann-La Roche
Breast Neoplasms, Breast Cancer Detection
Diagnostic Accuracy of Carebot AI MMG in Mammography Screening: Multicenter MRMC Study
This study evaluates the diagnostic performance of Carebot AI MMG, an artificial intelligence (AI)-enabled medical device for evaluating mammograms.
- Conditions
- Breast Neoplasms, Breast Cancer Detection, Breast Cancer - Female, Breast Cancer Screening
- Trial name
- CARE-MMG-MRMC (NCT07298252)
- Testing
- Carebot AI MMG software analysis
- Where
- 4 sites in Czechia, Slovakia
- Volunteers
- 222 people, healthy volunteers welcome
- Sponsor
- Carebot s.r.o.
Moderate or Severe Opioid Use Disorder
A Multiple Dose Opioid Challenge Study
Multi-site, randomized, double-blind, repeat-dose Phase 2 study to evaluate the degree and duration of action of multiple doses of CAM2038 in blocking the effects of hydromorphone in patients with moderate or severe opioid use…
- Trial name
- NCT02611752
- Testing
- CAM2038
- Where
- 3 sites in United States
- Volunteers
- 47 people
- Sponsor
- Braeburn Pharmaceuticals
Multiple Myeloma, Melanoma
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
This is a first-in-human trial proposed to test HLA-A*0201 restricted NY-ESO-1 redirected T cells with edited endogenous T cell receptor and PD-1.
- Conditions
- Multiple Myeloma, Melanoma, Synovial Sarcoma, Myxoid/Round Cell Liposarcoma
- Trial name
- NCT03399448
- Testing
- NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Pennsylvania
Peritoneal Cancer, Ovarian Cancer
A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer
This study was designed to find out how effective and safe GW786034, is in the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer that has not responded to standard treatment.
- Conditions
- Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer
- Trial name
- NCT00281632
- Testing
- GW786034
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 35 people
- Sponsor
- GlaxoSmithKline
Cancer, Pain
Long-term Safety and Efficacy Study of Fentanyl Sublingual Spray for the Treatment of Breakthrough Cancer Pain
The purpose of this study was to assess the 90-day safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain in subjects on around-the-clock opioids for their persistent cancer pain.
- Trial name
- NCT00538863
- Testing
- Fentanyl sublingual spray
- Where
- 52 sites in United States, Canada and 1 more
- Volunteers
- 319 people
- Sponsor
- INSYS Therapeutics Inc
Multiple Myeloma
An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants
The purpose of this study is to describe contemporary, real-world patterns of participant characteristics, clinical disease presentation, therapeutic regimen chosen, and clinical outcomes in participants with newly diagnosed [ND]…
- Trial name
- NCT02761187
- Testing
- No Intervention
- Where
- 137 sites in United States, Belgium and 13 more
- Volunteers
- 4,253 people
- Sponsor
- Takeda
Multiple Myeloma
BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma
This is a prospective, non-inferiority study comparing VRD±D followed by BCMA CAR-T cell therapy versus VRD±D followed by autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma…
- Trial name
- CAREMM-006 (NCT06793449)
- Testing
- anti-BCMA CAR-T, ASCT
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.